Dysregulation of the Wnt/b-catenin pathway has been observed in various malignancies, including acute myeloid leukemia (AML), where the overexpression of b-catenin is an independent adverse prognostic factor. b-catenin was found upregulated in the vast majority of AML samples and more frequently localized in the nucleus of leukemic stem cells compared with normal bone marrow CD34 þ cells. The knockdown of b-catenin, using a short hairpin RNA (shRNA) lentiviral approach, accelerates alltrans retinoic acid-induced differentiation and impairs the proliferation of HL60 leukemic cell line. Using in vivo quantitative tracking of these cells, we observed a reduced engraftment potential after xenotransplantation when b-catenin was silenced. However, when studying primary AML cells, despite effective downregulation of b-catenin we did not observe any impairment of their in vitro long-term maintenance on MS-5 stroma nor of their engraftment potential in vivo. Altogether, these results show that despite a frequent b-catenin upregulation in AML, leukemia-initiating cells might not be 'addicted' to this pathway and thus targeted therapy against b-catenin might not be successful in all patients.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous human disease defined by an accumulation of immature myeloblasts in the bone marrow and peripheral blood. Like other cancers, AML is a multi-step process characterized by the alteration of different pathways affecting cell proliferation and myeloid differentiation. 1 Over the last few years, it has been recognized that AML is maintained by leukemic stem cells (LSCs), which are capable of initiating and sustaining leukemic growth. [2] [3] [4] [5] [6] These LSCs possess self-renewal capacity, as demonstrated by serial transplantation experiments. However, the detailed mechanisms and pathways responsible for the maintenance and/or acquisition of such properties remain poorly characterized. Different pathways have been postulated to be critical for LSC selfrenewal, such as Bmi1, Hox genes, Hedgehog, Notch and Wnt/ b-catenin. [7] [8] [9] [10] The canonical Wnt/b-catenin pathway 11 has a critical role in self-renewal of hematopoietic stem cells (HSCs) and its dysregulation has been suggested in LSCs. 12, 13 There is evidence that Wnt expression can inhibit the differentiation of HSCs, whereas overexpression of Axin (an antagonist of b-catenin activation) has an inhibitory effect on Wnt signaling, which in turn results in a decrease in HSCs number. 12 Moreover, the addition of purified Wnt3a ligand in ex vivo culture has been used successfully to expand HSCs. 14 Nevertheless, the role of b-catenin (encoded by the CTNNB1 gene) in normal murine HSCs remains controversial. Indeed, it has been reported that HSCs overexpressing b-catenin acquired enhanced proliferation but were unable to engraft in irradiated mice. 15 A more recent study, focusing on the specific deletion of b-catenin in different hematopoietic lineages, reported that although the loss of b-catenin did not impair the formation of HSCs, these HSCs exhibited a deficit in long-term growth and maintenance. On the contrary, it has been reported that constitutive activation of b-catenin causes a multilineage block in differentiation and compromises HSC maintenance by enforcing the cycling of HSCs, with the consequence of exhausting the long-term stem cell pool. 16, 17 In a leukemia setting, Zhao et al. 18 have elegantly shown that different b-catenin levels lead to divergent effects in a Bcr-Abl model of leukemogenesis. In their study, conditional b-catenindeficient mice were generated and they showed that the loss of b-catenin expression in the hematopoietic compartment decreased the incidence of chronic myeloid leukemia. They were able to rescue this phenotype by ectopic b-catenin expression, but interestingly only with low levels of b-catenin. High doses of b-catenin were detrimental to leukemogenesis. Therefore, the levels of b-catenin, in addition to the activation status of the protein, can determine its complex proor anti-tumorigenic function. Most of the published work studying human LSC self-renewal and the implication of Wnt/b-catenin pathway has examined chronic myeloid leukemia. 19 In chronic myeloid leukemia blast crisis, it has been shown that granulocyte-macrophage progenitors express high levels of Bcr-Abl and had an activated Wnt-b-catenin pathway, with nuclear localization of b-catenin. 20 As assessed via replating assays, they had enhanced replating capacity, which was inhibited by a specific Wnt pathway antagonist, Axin. Chronic myeloid leukemia-granulocyte-macrophage progenitor also have self-renewal capacity in serially transplanted NOD/SCID mice and display an in-frame splice deletion of the glycogen synthase kinase (GSK) 3b kinase domain, which could explain enhanced b-catenin expression. 21 To date, no b-catenin mutations have been found in AML, but there are other ways by which dysregulation of this pathway can occur. An increase in Flt3 signaling (via mutations/amplifications) leads to Akt-mediated phosphorylation and inactivation of GSK3b, resulting in the stabilization of b-catenin and thus to increased activation of Wnt signaling. 22 An increase in Frizzled-4, a Wnt receptor that is induced by certain Flt3 mutations, leads to an activation of b-catenin too, and consequently to an augmentation of T-cell factor/lymphoid enhancer factor (TCF/LEF) activity and MYC transcription. 23 Translocation products, such as AML1-eight twenty-one (ETO) and promyelocytic leukemia zinc finger-retinoic acid receptor alpha (PLZF-RARa) were also reported to activate the Wnt/b-catenin pathway, by activating plakoglobin. 24 Furthermore, recent reports indicate that abnormal promoter methylation of specific Wnt inhibitors (that is, sFRP1, sFRP2, SFRP4 sFRP5, WIF1, DKK3 and Hdpr1) can enhance Wnt/b-catenin signaling in acute lymphoblastoid leukemia and AML. 25, 26 The first piece of evidence for the importance of b-catenin in AML patients comes from the work of Ysebaert et al., 27 who a few years ago retrospectively analyzed 118 patients for b-catenin expression by western blot and correlated b-catenin levels to survival. They identified b-catenin as a new and independent negative prognostic factor predicting poor eventfree survival and shortened overall survival. At the level of the LSC in AML, only one report showed that the Wnt/b-catenin signaling pathway was dysregulated, with a paradoxical overexpression of CK2, Axin and adenomatous polyposis coli (APC), which are all negative regulators of this pathway. 28 Very recently, however, in the study of Yeung et al. 29 we concluded that in a mixed lineage leukemia mouse model of AML, the level of b-catenin was also critical for understanding the functional difference between pre-LSCs and LSCs. We went on to show that this pathway was also critical for the ex vivo maintenance of human leukemia.
Furthermore, Siapati et al. 30 demonstrated the relevance of the Wnt/b-catenin pathway in AML cell lines. The question of whether or not this pathway is actually essential for the growth and maintenance of LSCs in all AML patients showing activation of bcatenin still needs to be addressed. To this end, in this study, we investigated the effect of down-modulation of b-catenin in AML patients exhibiting different levels of b-catenin activation, and show that not all patients are sensitive to this inhibition.
Materials and methods

Cells and human samples
The HL60 human leukemic cell line was obtained from American Type Culture Collection, Manassas, VA, USA. AML cells were obtained from patients at St Bartholomew's Hospital, London, UK after informed consent in accordance with the Declaration of Helsinki. Most samples were screened for their ability to engraft in immunodeficient mice before use in this study ( Table 1 ). The protocol, as well as the obtention of cadaveric normal bone marrow (NBM) cells, was approved by the East London Ethical Committee.
Human b-catenin knock down
We used the pGIPZ lentivirus from OpenBiosystems (Epsom, UK), which expresses a green fluorescent protein (GFP) cassette, as the empty vector. The target sequences from 5 0 to 3 0 was GCTCCTTCTCTGAGTGGTAAA (targeting the position 396-417 of human b-catenin gene, sh22). 29 The same target sequence was inserted in another lentivector with an EF1a promoter instead of cytomegalovirus (sh47). For the non-silencing scramble short hairpin RNA (shRNA), CGGACTTGAATGGAAT GATAAT was the target sequence.
Real-time polymerase chain reaction (quantitative PCR)
RNA samples were isolated using RNeasy Mini kit (Qiagen, Crawley, UK) and reverse transcribed to complementary DNA using either Superscript III (Invitrogen, Paisley, UK) or Omniscript Reverse transcriptase kits (Qiagen). Quantitative PCRs (qPCRs) were run in duplicate on an ABI 7900HT qPCR instrument equipped with SDS 2.3 software, using either SYBR Green or Power SYBR Green PCR master mix (Applied Biosystems, Warrington, UK). Results were normalized to glyceraldehyde 3-phosphate dehydrogenase or b-actin via the 2 ÀDDCt method.
Western blotting
Western blot analysis was performed using previously published standard techniques. Hybond-C nitrocellulose membranes (Amersham Bioscience, GE Healthcare, Little Chalfont, UK) were probed with mouse anti-human b-catenin clone14/b-catenin (BD Pharmingen, Oxford, UK) or mouse antib-actin (Sigma Aldrich, Dorset, UK) antibodies. Donkey antimouse immunoglobulin G-horseradish peroxidase sc-2314 (Santa Cruz Technology, Santa Cruz, CA, USA) was used as a secondary antibody. Detection was achieved with Amersham ECL Plus Western Blotting reagent (GE Healthcare) according to the manufacturer's instructions. Abbreviations: AML, acute myeloid leukemia; Biphenotypic, lymphoid and myeloid markers; FAB, French-American-British classification; FLT3 ITD, FMS-like tyrosine kinase internal tandem duplication; M4Eo, M4 with eosinophilia subtype; NA, not assessed; NPM Mut, nucleosphosmin mutated; NSG, NOD/SCID/gamma c null; LSC, leukemic stem cells; WBC, white blood cells count, expressed as Â 10 9 per liter of blood. Mutation analysis sequencing was performed using previously published methods. For each patient tested, we also investigated in parallel the phenotype of the LSCs. It has been shown in the late 1990s that AML is organized as a hierarchy that originates from a primitive LSC which has the CD34 + CD38 À phenotype. [2] [3] [4] [5] But lately we showed that the anti-CD38 antibody used for sorting can have a negative effect on the repopulating capacity of the LSC in in vivo models 31 and that CD34 À AML cells can contain LSC, particularly in AML patients with mutated NPM 32 . Therefore, all four fractions of cells (CD34 À CD38 À , CD34 + CD38 + , CD34 + CD38 À and CD34 À CD38 + ) were tested for their ability to engraft in NSG mice. From these results, we determined the phenotype of the LSCs, which was used when looking at the expression and intra-cellular localization of b-catenin.
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Flow cytometry analysis
Antibodies for flow cytometry were purchased from BD Biosciences (Oxford, UK), except b-catenin APC (R&D Systems, Abingdon, UK) and Alexa Fluor 647 anti-human CD38 clone HIT2 (Biolegend, Cambridge, UK), and used as described in their respective Materials and methods sections. The cells were analyzed using an LSRII cytometer (BD, Oxford, UK) and DIVA software and/or FlowJo (Tree Star, Olten, Switzerland). Cells were sorted using either MoFlo (DakoCytomation, Fort Collins, CO, USA) or Aria (BD) cell sorters. Gates were set up to exclude non-viable cells and debris. The negative fraction was determined using appropriate isotype controls. For intracellular b-catenin assessment, 5 Â 10 6 cells were stained with phycoerythrin-conjugated CD34 and Alexa Fluor 647-conjugated CD38 antibodies for 30 min at 4 1C. Cells were then washed in phosphate-buffered saline (PBS) containing 2% fetal calf serum and fixed with paraformaldehyde 2% for 10 min before permeabilization for another 10 min in PBS with 0.1% Triton X-100 (Sigma Aldrich). The cells were washed and stained with APC-conjugated anti-b-catenin (1:25) for 1 h. Then they were washed in PBS and resuspended in PBS with 0.2% fetal calf serum and 1 mg/ml 4 0 ,6-diamidino-2-phenylindole (DAPI).
Imaging flow cytometric assessment of b-catenin nuclear residency
The ImageStream imaging flow cytometer (Amnis Corporation, Seattle, WA, USA) was used to quantify the degree of b-catenin nuclear internalization on large numbers of CD34 À and CD34 þ sub-populations from AML and NBM patients. Briefly, samples were first stained with fluorescently labelled antibodies against extracellular markers, followed by fixation, permeabilization then intracellular staining with b-catenin fluorescein isothiocyanate antibody for 1 h. After washing, cells were resuspended in PBS with 0.2% fetal calf serum containing 0.1 mg/ml DAPI before acquisition on the ImageStream system (Amnis Corporation). A minimum of 1 00 000 total events were collected along with single color control files for spectral compensation. All compensation and data analysis were performed post-acquisition using the IDEAS 4.0 software package (Amnis Corporation). The fluorescence image-based method for quantifying nuclear residency of b-catenin relies on the spectral isolation of b-catenin signal image from the DAPI stained nuclear image. 33 Full details of how b-catenin nuclear internalization was measured can be found in the Supplementary Information.
Lentivirus production and viral transduction
Viral particles were produced by transient calcium-phosphate co-transfection of 293T cells with the relevant vector plasmid, plus an encapsidation plasmid lacking Vif-, Vpr-, Vpu-and Nefaccessory human immunodeficiency virus-1 proteins (pD8.74), and a vesicular stomatitis virus envelope expression plasmid (pMDG2) (Plasmidfactory, Bielefeld, Germany). Lentiviral particles were concentrated after ultracentrifugation at 19 000 r.p.m. (61 600 g) for 150 min and stored at À80 1C in StemSpan medium (StemCell Technologies, Vancouver, Canada).
Human HL60 cells were pre-stimulated overnight on MS5 stromal culture in StemSpan supplemented with recombinant human interleukin-3 (IL3), granulocyte colony-stimulating factor, thrombopoietin (Peprotech, London, UK; 20 ng/ml each). Cells were then plated at 10 6 cells per ml in serum-free medium StemSpan (StemCell Technologies), supplemented with 4 mg/ml polybrene (Sigma Aldrich) and the following recombinant human cytokines: 100 ng/ml stem cell factor, 100 ng/ml Flt3 ligand, 60 ng/ml IL3, 10 ng/ml thrombopoietin. Multiplicity of infection 10 to 30 for HL60 cell line was used for overnight transduction of cells either with control or silencing lentivirus in standard conditions of culture (humidified atmosphere, 37 1C 5% CO 2 ) and the next day cells were washed before any further analysis or plating.
Long-term culture and limiting dilution assay (LDA)
For AML samples, after thawing, the pre-stimulation period was shortened to 4 h without exposure to MS-5 cells, the other steps remaining unchanged (see Lentivirus production and viral transduction section). For LDA purposes, ex vivo culture of lentivirally transduced AML samples (multiplicity of infection 30) was then performed on MS-5 stromal layer in the presence of 20 ng/ml each of recombinant human IL3, granulocyte colonystimulating factor and thrombopoietin in MyeloCult H5100 media (StemCell Technologies). 34, 29 Co-cultures were established in triplicates per condition and for each time point assessed (72 h, and weeks 1, 2 and 3). Culture medium was replenished by a bi-weekly half-medium change. After trypsinization, cells were stained with various markers including anti-murine Sca1-phycoerythrin and antihuman CD45-APC antibodies (see Flow cytometry analysis section) and only CD45 þ Sca1 À cells were further analyzed and sorted.
For LDA assays, after the initial 3 weeks culture period, transduced AML cells were sorted for the presence of GFP and seeded in replicates onto a new MS-5 stromal layer at various seeding densities (ranging from 50 to 5000 cells per well of a 96well plate). Scoring of positive wells for proliferation was done after 3 weeks.
Differentiation/morphology analysis
Differentiation of HL60 cells was induced with 1 mM all-trans retinoic acid (ATRA) (Sigma Aldrich) for 7 days. 35 After resuspension in PBS, cells were centrifuged in Cytofunnel devices at 500 r.p.m. for 10 min and then stained with May-Grünwald Giemsa solution (Fluka, Dorset, UK). Images from slides were acquired using a Zeiss Axiovert 40CFL microscope ( Â 364 magnification field) equipped with a Carl Zeiss Canon Power Shot A640 camera (One Zeiss Drive, Thornwood, NY, USA).
Cell cycle analysis, apoptosis, cell counts
For cell cycle analysis, cells were deprived of serum for 18 h to synchronize them, then after centrifugation, were fixed in 2% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 10 min and resuspended in PBS containing 2% fetal calf serum and 1 mg/ml DAPI. Cell viability was assessed by DAPI and via Annexin V staining (BD Pharmingen). CountBright absolute counting beads (Molecular Probes, Invitrogen, Paisley, UK) were used to assess the absolute number of cells originally present in each tube.
Apoptotic cells were hypodiploid, G1 phase cells were identified as Ki67-positive and with 2n DNA content, cells in S phase were those with a DNA content ranging from 2n to 4n, and cells in G2/M phase had a 4n DNA content.
Colony-forming unit (CFU) assays
Virally transduced HL60 were plated in triplicate at a density of 500 cells per ml of H4330 MethoCult media (StemCell Technologies) supplemented with 1% penicillin/streptomycin 
Animals and xenotransplantation (NOD/SCID assay)
All animal experiments were performed in accordance to the Home Office and Cancer Research UK regulations. NOD/SCID and NOD/SCID/b2-microglobulin null or NOD/SCID/gamma c null male and female mice were obtained from Charles Rivers Laboratories (Moorgate, UK), hosted in micro-isolators and fed sterile food and acidified water. In all, 8-to 12-week old mice were irradiated at 375 cGy ( 137 Cs source) 16 to 24 h before intravenous injection of cells. Mice were transplanted with 20 000 to 4 00 000 AML-transduced cells. Animals transplanted with primary AML cells were killed at 12 weeks. Bone marrow from all femurs, tibias and pelvis were either flushed or crushed in PBS. Red blood cells were then lyzed with ammonium chloride.
Cells were stained with mouse anti-human antibodies against CD19, CD33 or CD45. Rat anti-mouse CD45 antibody was used as a negative marker. AML engraftment was considered as the CD45 þ CD33 þ CD19 À population. Where there was a doubt as to the origin of engrafted cells, we assayed the cells for leukemia-specific mutations, where possible.
In vivo bioluminescence imaging HL60 cells were first transduced with a lentiviral vector expressing the luciferase reporter gene (Firefly luciferase-Red fluorescent protein (RFP)) (multiplicity of infection 10). The TWR Luc À Fluc þ RFP plasmid was a kind gift of Dr R De Maria (Istituto Superiore di Sanità, Rome, Italy). In this construct, the luciferase cassette was placed under the control of cytomegalovirus promoter and the RFP cassette was under the PGK promoter.
RFP-positive cells were then transduced with the lentivirus containing either the scramble control GFP or the b-catenin GFP shRNA (multiplicity of infection 10), and sorted again on GFP and RFP. An aliquot of these cells was analyzed on the IVIS Spectrum system to check for luciferase activity after addition of luciferin (150 mg/ml final concentration) (Caliper Life Science, Hopkinton, MA, USA). In all, 8 to 10 weeks old NOD/SCID/b2microglobulin null mice were sublethally irradiated with 375 cGy 24 h before intra-tibial injection of 5 Â 10 6 luciferasetransduced HL60 cells. In vivo optical imaging was performed using IVIS Spectrum bioluminescence-fluorescence optical imaging system (Caliper Life Science, Runcorn, UK) at 24 h, and after 1, 2, 3 and 4 weeks. Before imaging, each mouse was given an intraperitoneal injection of 125 mg/kg luciferin 32 (Caliper Life Science). General anesthesia was induced with 3% isoflurane and the mouse was placed in a light-tight heated chamber. After acquiring bright-field images of each mouse, anterior and posterior luminescent images were then successively acquired with 1-to 5-min exposure time. 36 Optical images were displayed and analyzed with the IVIS Living Image software (Caliper Life Science). Regions of interest were manually drawn around the bodies of the mice to assess the emitted signal intensity and sum of the anterior and posterior measurements were used as the total bioluminescence signal for each mouse. Optical signal was expressed as photon flux. In order to account for inter-individual variability, data were normalized by determining the proliferation index (as reflected by the ratio of bioluminescence imaging (BLI) activity between two time points) for each animal.
Statistical analysis
Significances of human AML patient co-culture data, including LDA, and colony assays comparisons were determined as previously published. 29 Pearson's correlation coefficient was used to determine R 2 values whereas we tested for non-zero slope by calculating the appropriate t-statistic. The Kruskal-Wallis and Mann-Whitney U-tests were used to assess the statistical significance of the differences observed between groups. The threshold for statistical significance (*) of P-values was 0.05.
Results
Expression and activation of b-catenin in AML samples
We found by qPCR that b-catenin was overexpressed compared with CD34 þ NBM in 13 out of 17 (76%) primary AML samples (Figure 1a ). However, no correlation was found between b-catenin expression and French-American-British subtype, karyotype, Flt3 or nucleophosmin (NPM) status in our cohort. At the protein level, compared with NBM, the expression of intra-cellular bcatenin in AML samples determined by flow cytometry was increased in 10 out of 17 (58%) samples (Figure 1b ). In these samples and as expected because of b-catenin posttranslational regulation by the APC/GSK3b/Axin complex, b-catenin protein levels did not correlate with mRNA levels assessed by qPCR ( Supplementary Figure S1 ). Indeed, out of the 13 samples in which b-catenin was overexpressed at the mRNA level, only 8 (62%) also overexpressed b-catenin at the protein level compared with NBM (data not shown). As b-catenin was nonetheless found overexpressed at the mRNA and/or the protein level in 15 out of 17 samples (88%), we checked its expression in CD34 þ and CD34 À cell fractions from both AML and NBM samples. There was no direct correlation between the percentage of CD34 þ cells and the protein level of b-catenin in AML samples (R 2 ¼ 0.12, data not shown). Moreover, the mean fluorescence intensities values for b-catenin were not statistically significantly higher in the CD34 þ populations than in their CD34 À counterparts, both for AML samples and NBM and also in AML versus NBM (Figure 1c ).
We further confirmed that the Wnt/b-catenin was actually activated, by determining the degree of b-catenin nuclear residency in AML samples overexpressing b-catenin, using the ImageStream system (Figure 2 and Supplementary Figure S2 ). Using this approach, we observed that proportionally b-catenin was significantly more localized in the nucleus of CD34 þ cells from all AML patients tested compared with those from NBM (Figure 2c ), clearly reflecting an increase activation of the Wnt pathway. Considering that not all LSCs reside within the CD34 þ population (see Table 1 footnote), where appropriate, we determined the level of b-catenin residency within the LSC compartment of patients to check whether b-catenin was indeed active in the actual LSC fraction of the tested patients, as defined by their properties to engraft in NOD/SCID mice. Once again, we were able to record that significantly more b-catenin was localized in the nucleus of the LSCs compared with that of CD34 þ NBM cells (Figure 2d ). Collectively, these data support the conclusion that in most but not all AML samples, Wnt/bcatenin is over-activated and that this is a feature shared by LSCs regardless of their CD34 status.
The activation of other members in the Wnt/b-catenin pathway was further confirmed by screening the mRNA levels of 84 genes related to this pathway for seven patients in which b-catenin was overexpressed compared with CD34 þ NBM (Supplementary Table 1 ). As expected from Figure 1a , b-catenin b-catenin in AML samples A Gandillet et al was vastly upregulated in these samples. Genes upstream or downstream of b-catenin were found differentially expressed, with target genes such as TCF1 and TCF3 being generally upregulated, whereas TCF-4, LEF-1 and in some patients cyclin D1 (unlike cyclins D2 and D3) were underexpressed compared with CD34 þ NBM, suggesting a feedback mechanism. Wnt ligands, Frizzled receptors, LPR5/6, Jun, MYC, DKK1, were upregulated in most patients whereas GSK3b expression was differently affected depending on the patients studied.
Effect of the transduction of shRNA b-catenin on HL60 proliferation in vitro
In order to understand the role of overexpression of b-catenin in AML samples, we first down-modulated its expression in leukemic cell lines. The HL60 cell line was chosen because it could engraft in immunodeficient animals and because in our hands the knockdown efficiency was greater than in Fujioka cells, which also express b-catenin (data not shown).
HL60 cells were transduced and sorted at day 4 based on GFP expression to have a homogeneous population (purity 497%) expressing either a control shRNA or a shRNA against b-catenin (sh22 or sh47) (see Materials and methods section). b-Catenin was significantly and consistently found to be decreased at the mRNA level (80-95% knockdown) (Figure 3a HL60-transduced cells showed only mild but consistent defects in proliferation in the initial stages (Figure 3b , left panel) with no difference in cell cycle status revealed at day 8 by flow cytometry (Figure 3b, right panel) . qPCR analysis at day 8 indicated that the silencing was still effective and that apoptotic and pro-apoptotic genes were differentially expressed (Supplementary Figure S3 ). Consistently, the proportion of cells positive for Annexin V was slightly greater in the knocked-down cells versus control (Figure 3c ), however, these effects did not increase over time. Indeed, the proliferation kinetics and apoptosis from GFP þ cells sorted at D8 (that is, at the end point of original kinetics) were similar to that of control (data not shown).
We next looked at the potency of b-catenin silenced HL60 cells to form hematopoietic colonies. Silenced cells were less potent to do so (Figure 3d, lower panel) , moreover the morphology of the colonies (Figure 3d, upper panel) was consistent with such a defect in proliferation. To investigate the extent of b-catenin silencing effects on myeloid differentiation, the production of granulocytes precursors was measured after the induction of myeloid differentiation with 1 mM ATRA for 4 days after transduction. Downregulation of b-catenin lead to a higher myeloid differentiation in HL60 cell line incubated with 1 mM ATRA, the cells being more mature as shown by an increased proportion of metamyelocytes and bigger cytoplasmic azurophilic granulations. As shown in Figure 3e , in the presence of ATRA, there was an average of 70% metamyelocytes/ granulocytes in sh b-catenin condition compared with 23% in control condition. Without ATRA, a maximum of 2% differentiated cells was observed in both conditions. We confirmed these findings by flow cytometry with an increase in the expression of the granulocytic marker CD11b, which was expressed in 94% of sh22-transduced cells against only 61% in control after ATRA exposure (data not shown). Similar findings were obtained with 1.3% dimethylsulfoxideFanother inducer of differentiation (data not shown). Altogether, these data suggest an early impact of the downregulation of b-catenin in HL60.
Effect of b-catenin silencing on HL60 behavior in vivo
To follow on our in vitro data, we wanted to assess whether HL60 leukemic cell proliferation was dependent in vivo on b-catenin and thus if its silencing had an effect on bone marrow engraftment in NOD/SCID/b2-microglobulin null recipient mice. After intra-tibial injection of double-transduced HL60 cells with luciferase either shRNA against b-catenin or control, the proliferation and trafficking of the cells was non-invasively 
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A Gandillet et al and longitudinally monitored by BLI at different time points ranging from 24 h to 4 weeks. This allows us to follow the tumor development based on luciferase signal intensity (Figure 4a ). The endpoint data show a highly significant difference in cell proliferation between both conditions (P ¼ 0.01). As expected, b-catenin silencing alone was not sufficient for preventing leukemic cells to proliferate since a 52-fold increase in BLI signal was observed between day 1 and week 4 in the b-catenin silenced group. However, at least a sub-population of cells was affected, because in the control group the BLI signal increase was 447-fold, that is, about eight times more than with silencing ( Figure 4b ). Despite individual variations, the average bone marrow engraftment at 4 weeks was also significantly affected with 20.2% in the control versus 3.3% in the b-catenin silenced group (Figure 4c , P ¼ 0.02), corroborating the BLI data. Taken together, these in vivo data demonstrate that, at least in HL60 cells, b-catenin is involved in integration and/or transduction of signal emanating from the micro-environment and remains sensitive to environmental cues, whereas they could grow in a stroma-independent way in vitro. Having found such a crucial role for b-catenin in vivo, we wondered whether this could also be true for primary AML samples.
Effect of b-catenin silencing in primary AML samples in vitro and in vivo
A major critical point for assessing the effects of b-catenin silencing in primary AML cells was to select patient samples with pre-assessed high engraftment potential in NOD/SCID or NOD/SCID/gamma c null mice, and high frequency of leukemic-initiating cells (LICs), and of course for the purpose of our study, an increased level of b-catenin. With these parameters we chose patients 1, 5 and 9. These patients had variable levels of b-catenin overexpressionFhigh (patient 1), medium (patient 5) and relatively low (patient 9)F among the 17 AML samples tested (see Figure 1 ).
The level of knockdown of b-catenin mRNA was consistently 480% after 1 week (Supplementary Figure S4) . Silencing of b-catenin was also confirmed at the protein level by flow cytometry and ranged from 50 to 68% (data not shown). In order to directly assess the function of b-catenin in LIC from primary AML samples, in vitro long-term culture on MS-5 stroma and in vivo experiments were carried out. In a preliminary experiment, we observed that b-catenin knockdown significantly reduced the number of CFU-blasts in vitro ( Supplementary Figure S5) , indicating that, like in the HL60 cell line, some progenitors were dependent on b-catenin signaling. In long-term culture, the level of GFP þ cells gradually decreased in patients 5 and 1, but was stable in patient 9 (Figure 5a ). However, we did not see any significant differences between the knockdown and the control group in any of the three patients tested. We then sorted GFP þ cells after 3 weeks and assessed by LDA the frequency of leukemia cultureinitiating cells (LC-ICs). The LC-IC frequency in knockdown versus control was similar in all three patients ( Table 2 ). We thus confirmed that the downregulation of b-catenin and of some downstream effectors was still effective by performing qPCR on GFP þ sorted cells at 3 weeks (Table 3 ). These data show that at least in the AML patients tested here, LC-ICs despite being efficiently targeted by b-catenin knockdown, were insensitive to this downregulation. To confirm this lack of effect, we assessed the b-catenin silencing effect on the AML engraftment potential in the NOD/SCID/b2-microglobulin null mice. The engraftment of the transduced AML cells was assessed at week 12. We found no significant decrease in the level of engraftment for the b-catenin silenced condition in all cases studied (Figure 5b) , with a nonsignificant decreaseFeven for patient 1 (expressing the highest level of b-catenin)Fin the proportion of GFP þ silenced cells compared with control ( Supplementary Figure S6) . In patients 5 and 9, we were able to perform LDA of LC-ICs from GFP þ cells harvested from the primary transplanted mice. We again show no change in the frequency of LC-ICs when comparing knockdown to control (Table 4) , and this was also the case when comparing the GFP þ versus GFP À fraction for each condition (data not shown).
Taken together, our data show that the downregulation of b-catenin has no effect on LC-ICs or LICs in the patients tested here.
Discussion
The emerging role of Wnt signaling in AML has been increasingly investigated in recent years and b-catenin has been suggested as a pivotal player in this disease. 13 In spite of the fact that b-catenin protein levels could well differ from mRNA levelsFprobably due to the posttranslational regulation of b-catenin by the APC/GSK3b/Axin complexFwe To test the impact of the loss of function of b-catenin in AML, we first transduced HL60 leukemic cells with efficient shRNAs against b-catenin and observed a decrease in cell proliferation, concomitant with a slight initial increase in apoptosis. At the mRNA level, the target genes of b-catenin, like cyclin D1 and MYC, were affected, as were some apoptotic and pro-apoptotic genes. Cyclins D2 and D3 genes were downmodulated, which is consistent with the observed reduced proliferation of HL60 cells over 8 days in culture. Another effect that we noted on silencing of b-catenin, is the strikingly enhanced myeloid differentiation of the HL60 cell line after ATRA induction, which is consistent with previous data showing that the constitutive activation of b-catenin blocks multilineage differentiation, 17 resulting in a severe loss of Gr1 þ CD11b þ cells in recipient mice. Moreover, we show in the CFU-blast assays a decrease in the number as well as in the size of silenced cells compared with control. After in vivo transplantation in immunodeficient mice, we found that the engraftment potential of b-catenin silenced HL-60 cells was significantly decreased, which is consistent with a recent report by Siapati et al. 30 Taken together, these in vitro and in vivo data using HL60 leukemic cells demonstrate that b-catenin has a pivotal role in the control of the balance between proliferation and differentiation.
When looking at the effect of b-catenin knockdown in AML patients' samples, we show that the silencing decreased significantly the number of CFU-blasts as previously reported, 29 which indicates that at least some of the leukemic blasts/ progenitors are sensitive to the knockdown of b-catenin. In the first 3 weeks of co-culture, the number and percentage of GFP þ cells diminished over time but not differently or preferentially in the silenced group over control conditions. Patient sample 9 was barely affected at all. This was true for the three samples studied despite their differences in the level of b-catenin. Of note, primary LDA of LC-ICs of GFP þ cells after 3 weeks did not reveal any difference compared with control. This finding is Table 2 Limiting dilution assay for primary human AML cells after MS-5 long-term co-culture with or without b-catenin knockdown Abbreviation: GFP, green fluorescent protein.
All data were normalized to b-actin and to respective control (empty vector) condition. Abbreviations: AML, acute myeloid leukemia; GFP, green fluorescent protein; LC-IC, leukemia culture-initiating cell; LDA, limiting dilution assay; NSG, NOD/SCID/gamma c null. After lentiviral transduction, human AML cells were transplanted in NSG mice and sorted at week 12 for GFP þ . LDA of LC-ICs was measured after an additional 3 weeks of culture from GFP þ sorted populations plated on MS-5 stroma layer. Empty vector was used as control.
b-catenin in AML samples A Gandillet et al contrary to what we reported for two mixed lineage leukemia translocated samples 29 using the same standard of techniques, where the frequency of LC-IC was greatly diminished after knocking down b-catenin. In the samples tested in this study, we further show that the pool of LSCs was unaffected. At 12 weeks, the level of leukemic engraftment in mice was comparable between the two groups (silenced and control). Moreover, there was no impairment of the LC-IC frequency estimated by secondary LDA obtained from AML GFP þ cells present in the primary transplants, which is the alternative to secondary transplants to test the self-renewal potential of the cells. Thus, this demonstrates that the self-renewal capacity of LSCs was not affected by the down-modulation of b-catenin.
To rule out a potential lack of efficient downregulation of b-catenin, we purified GFP þ cells after 3 weeks of culture and show that at the mRNA level, b-catenin was still efficiently silenced and target genes affected. What was particularly striking was the fact that even when the entire pathway was silenced, as in patient sample 9, we did not see any impact on either LC-ICs or LICs. Judging from the qPCR data, it seems that in some patients a compensatory mechanism potentially involved. It is also probable that other pathways, such as Notch or phosphatidylinositol 3 kinase can interact with Wnt signalling 13 and that at least in some cases the high levels of b-catenin may be more a consequence of the dysregulation of other pathways in LSCs.
Our data indicate that b-catenin targeting is unlikely to provide a universal target to eradicate AML LSCs in all AML patients. Nevertheless, our other report showing a sensitivity of mixed lineage leukemia-translocated AML patients 29 along with recent data from Siapati et al. 30 suggest that for some subsets, b-catenin silencing could be an option. Defining the group of patients who may be sensitive to b-catenin inhibition on its own or via a multi-targeted therapy approach 37 will be important in designing personalized treatment approaches.
